GC007g expanded and induced durable remission in patients with B-ALL relapsed after allo-HSCT, with manageable safety profiles. Gracell Biotechnologies Inc.
10 months ago
P1 data • Journal • CAR T-Cell Therapy
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
Donor-derived CD19 CAR T-cell expanded and induced durable remission in patients with B-ALL relapsed after allo-HSCT, with manageable safety profiles. Phase 2 clinical trial of GC007g is currently recruiting. B cell acute lymphoblastic leukemia, CAR-T
over 1 year ago
P1 data • CAR T-Cell Therapy • IO biomarker
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule)